人福医药：氟比洛芬酯注射液获得药品注册证书

Core Viewpoint - The approval of the drug "氟比洛芬酯注射液" by the National Medical Products Administration marks a significant milestone for the company, enabling it to sell the product in the domestic market and enhancing its product pipeline [1] Company Summary - The company’s subsidiary, 宜昌人福药业有限责任公司, received the drug registration certificate for氟比洛芬酯注射液, which is indicated for postoperative and cancer pain relief [1] - The company submitted the application for marketing authorization in December 2023, with a total R&D investment of approximately 35 million yuan [1] - The projected national sales for氟比洛芬酯注射液 in 2024 are estimated to be around 980 million yuan [1] Industry Summary - The approval signifies the company's qualification to market the drug domestically, which will further enrich its product pipeline [1] - Future sales performance may be influenced by industry policies and market conditions, indicating a level of uncertainty [1]